clinical trial · NCT07647237
A Clinical Trial of Multiple Doses of GR2301 Injection Combined With Phototherapy in Trial Participants With Vitiligo
Genrix (Shanghai) Biopharmaceutical Co., Ltd.·phase2·not yet recruiting·n = 116
VitiligoGR2301 injectionPlacebo
brief summary
This is a randomized, double-blind, placebo-controlled Phase Ib/II clinical trial of multiple subcutaneous injections of GR2301 in combination with phototherapy to evaluate the tolerability, safety, pharmacokinetics, and preliminary efficacy in trial participants with vitiligo. The trial will be conducted in two stages: a dose-escalation stage (Phase Ib) and an expansion cohort stage (Phase II).
started
Jun 1, 2026
primary completion
Jun 1, 2028
completion
Dec 1, 2028
last updated
Jun 15, 2026
official title
A Randomized, Double-blind, Placebo-controlled Phase Ib/II Clinical Trial of Multiple Subcutaneous Injections of GR2301 in Combination With Phototherapy to Evaluate the Tolerability, Safety, Pharmacokinetics, and Preliminary Efficacy in Trial Participants With Vitiligo
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol